Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed 35 enrolled Beth Christian Gilead Sciences · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A phase I dose escalation study of veltuzumab and milatuzumab in relapsed and refractory B-cell NHL. The phase I study will be followed by a pilot phase II study.

Timeline

Start: 2009-09
Primary completion: 2015-04
Completion: 2015-09

Publications

Results Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2015 Jun;169(5):701-10. doi: 10.1111/bjh.13354. Epub 2015 Apr 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	milatuzumab	Monoclonal antibody	8 mg/kg	Intravenous
Subject	milatuzumab	Monoclonal antibody	16 mg/kg	Intravenous
Subject	milatuzumab	Monoclonal antibody	20 mg/kg	Intravenous
Subject	veltuzumab	Monoclonal antibody	200 mg/m2	Intravenous

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Summary

Timeline

Publications

Drugs

Indications